Journal profile · Immunology
Vaccine
ISSN 0264-410X · eISSN 1873-2518 · Elsevier BV · ENGLAND · Weekly · Founded 1983
Vaccine: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.34; hybrid open access; APC about USD 3,620; median 106 days to acceptance (138 articles, last 24 months); community-reported acceptance: about 50%; 1,282 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Vaccine is published by Elsevier BV and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Vaccine Coverage and Hesitancy, Influenza Virus Research Studies and Respiratory viral infections research, together about 27.4% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
The official journal of The Japanese Society for Vaccinology.Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas (such as passive immunization) are welcomed. Vaccine publishes primary Research Papers, Review Articles, Short Communications, Conference Reports and Letters on the following topics:History of VaccinologyHuman Fungal/Parasite/Other VaccinesHuman Non-Infectious Disease Vaccines (cancer, allergy, other)Human Viral Vaccines: Basic ResearchNovel Pathogen Vaccines (Biodefense/High Consequence Pathogens/Emerging Diseases)Vaccine Acceptance/HesitancyVaccine Basic Science (Immunology/Animal Models)Vaccine EthicsVaccine Manufacturing and BioprocessingVaccine Operational Research (Evaluation/Epidemiology/Informatics/Models /BigData and Analytics)Vaccine Policy Legislation/Economics/Digital Health)Vaccine Regulatory Science (Implementation/Guidelines/Public Health)Vaccine Safety ScienceVaccine Technology (Vectors/Adjuvants/Delivery Systems/Nanotechnology)Veterinary Bacterial VaccinesVeterinary Fungal/Parasite/Other VaccinesVeterinary Viral VaccinesVisual Vaccinology Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions. We also invite authors to submit relevant basic science and clinical reviews, methodological articles, opinion and commentary pieces, visual pieces, and letters. Vaccine has an open access companion journal titled Vaccine: X.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Vaccine Coverage and HesitancySocial Sciences11.2%
- Influenza Virus Research StudiesMedicine9.7%
- Respiratory viral infections researchMedicine6.6%
- Viral gastroenteritis research and epidemiologyMedicine6%
- Pneumonia and Respiratory InfectionsMedicine5.5%
- Bacterial Infections and VaccinesImmunology and Microbiology5.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.1%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.34LetPub ·
- Impact factor (publisher)
- 3.4Publisher website ·
- CiteScore 2026-06
- 6.4LetPub ·
- CiteScore (publisher)
- 6.4Publisher website ·
- SJR 2026-06
- 1.19LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 164LetPub ·
- h-index
- 266OpenAlex ·
- i10-index
- 21,719OpenAlex ·
- 2-year mean citedness
- 3.34OpenAlex ·
- Self-citation rate
- 11.8%LetPub ·
- Share of gold OA articles
- 54.63%LetPub ·
Volume
- Articles per year
- 1,124LetPub ·
- Articles per year (publisher)
- 4Publisher website ·
Articles by year OpenAlex count · 33,200 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 850 | 520 | 328 |
| 2025 | 1,282 | 860 | 3,372 |
| 2024 | 1,048 | 708 | 6,925 |
| 2023 | 978 | 668 | 10,958 |
| 2022 | 1,035 | 783 | 16,401 |
| 2021 | 1,114 | 745 | 29,738 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
106 daysMedian, submission to acceptance · P25–P75 74 days – 149 days
- Acceptance to online
- median 7 days (138 articles)
- Submission to online
- median 115 days
- Sample
- 138 articles with submission and acceptance dates (2,493 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4.5 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- First decision after review
- 67 daysPublisher website ·
- Submission to acceptance
- 111 daysPublisher website ·
- Acceptance to publication
- 9 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,620 / EUR 3,390 / GBP 2,900 / JPY 448,990 | — | — | |
| Publisher website | USD 3,640 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 3,640 (excluding taxes). The amount you pay may be reduced during submission if applicable.Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Weekly
- Founded
- 1983
- ISSN
- 0264-410X
- Electronic ISSN
- 1873-2518
- Society / sponsor
- Japanese Society for Vaccinology
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Vaccine
What CAS zone is Vaccine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Vaccine is in Zone 3 of Medicine, and in Zone 3 of the minor category Immunology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Vaccine?
The latest impact factor listed by LetPub is 3.34; CiteScore 6.4, h-index 266.
How long does peer review take at Vaccine?
Based on the dates recorded on 138 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 106 days (interquartile range 74–149 days); authors report an average review time of about 4.5 months; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Vaccine?
According to LetPub and DOAJ records, Vaccine is indexed in SCIE and Scopus.
Is Vaccine open access, and what is the APC?
Vaccine is a hybrid journal. For open-access publication: APC about USD 3,620.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .